Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report

Sonia Gupta, Amandeep Rakhra, Vinay Thallapally, Joseph Nahas

Research output: Contribution to journalArticlepeer-review

Abstract

Immunosuppression is the cornerstone therapy for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) myopathy. Typical immunosuppressants such as corticosteroids, methotrexate, and azathioprine have been used in conjunction with removal of the offending agent, yet the use of rituximab is more limited in this type of myopathy. Reported here is a case of a patient who responded well to rituximab (RTX) after the standard immunosuppressants had failed. This case illustrates the importance of further studies to evaluate the role of RTX in anti-HMGCR myopathy

Original languageEnglish (US)
Pages (from-to)122-125
Number of pages4
JournalIntractable and Rare Diseases Research
Volume10
Issue number2
DOIs
StatePublished - May 2021

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Rituximab use for refractory anti-HMGCR immune-mediated necrotizing myopathy: A case report'. Together they form a unique fingerprint.

Cite this